Ralinepag Drug Asset Due Diligence Report 2026

This Ralinepag Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

NDA/BLA

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Ralinepag can convert its Small molecule drug profile and PGI2 receptor biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Ralinepag (query alias: ralinepag)
Modality / target	Small molecule drug; PGI2 receptor; PGI2 receptor agonists
Highest global status	NDA/BLA
Originator	Arena Pharmaceuticals, Inc.
Active developers	United Therapeutics Corp., MannKind Corp., Everest Medicines (US) Ltd.

The MCP disease footprint includes Pulmonary Arterial Hypertension, Connective Tissue Diseases, Familial Primary Pulmonary Hypertension. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT03683186	Phase 3	Enrolling by invitation	1000	Number of subjects with treatment-emergent adverse events [Safety and Tolerability]
NCT03626688	Phase 3	Completed	687	Time from randomization to the first adjudicated protocol-defined clinical worsening event
NCT04084678	Phase 3	Terminated	10	Change From Baseline in Peak VO2 Assessed by CPET

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Ralinepag to Evaluate Safety and Effects on Exercise Capacity Assessed by CPET in Subjects With WHO Group 1 Pulmonary Hypertension Who Recently Initiated Therapy

Phase 3; n=10; evaluation: not stated. Reported fields: Change From Baseline in Peak VO2 Assessed by CPET(Median) = 0.929 mL/kg/min (Full Range, -0.73 to 2.59); Change From Baseline in Peak VO2 Assessed by CPET(Median) = -1.953 mL/kg/min (Full Range, -3.46 to -0.45); -

United Therapeutics Corporation Announces Ralinepag Achieved 55% Reduction in Risk of Clinical Worsening in Pivotal Pulmonary Arterial Hypertension Study, Delivering Exceptional, Highly Statistically Significant Efficacy

Phase 3; n=687; evaluation: Positive. Reported fields: Clinical worsening: HR = 0.45(95.0% CI, 0.33 - 0.62), P-Value = <0.0001 Met; Clinical worsening: HR = 0.45(95.0% CI, 0.33 - 0.62), P-Value = <0.0001 Met

420 - Initial Long-term Data From a Phase 3 Open-label Extension Study (ROR-PH-303) Evaluating Ralinepag for the Treatment of Pulmonary Arterial Hypertension (Advance Extension)

Phase 3; n=96; evaluation: Positive. Reported fields: AE = Adverse events in the OLE have been consistent with the known safety profile of prostacyclin therapies, with headache (69.8%), diarrhea (39.6%), and nausea (31.3%) reported most commonly. ; AE = Adverse events in the OLE have been consistent with the known safety profile of prostacyclin therapies, with headache (69.8%), diarrhea (39.6%), and nausea (31.3%) reported most commonly.

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Ralinepag addresses Pulmonary Arterial Hypertension, Connective Tissue Diseases, Familial Primary Pulmonary Hypertension. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 2 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2018-11-15	United Therapeutics partners with Arena to globally develop and market ralinepag for PAH.	Phase 3	US$800.0M upfront; US$400.0M milestones; US$1,200.0M stated total
2017-12-05	Arena Pharmaceuticals and Everest Medicines Enter into Development and Commercialization Partnership for Ralinepag and Etrasimod in China	Phase 2	US$12.0M upfront; US$212.0M milestones

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Ralinepag prodrugs and uses thereof”. The milestone feed surfaced a patent-application signal described as “Compositions comprising PGI2-receptor agonists and processes for the preparation thereof”. The milestone feed surfaced a patent-application signal described as “Compositions comprising PGI2-receptor agonists and processes for the preparation thereof”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Therapeutic index across KRAS/BRAF mutation subgroups
On-target toxicity and adaptive MAPK resistance
Lack of matched efficacy results in the current MCP result set

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO